CNS Pharmaceuticals (CNSP) Corporate Media Kit

CNS pharmaceuticals 24 Dr. Waldemar Priebe, Ph.D., Chairman of the Scientific Advisory Board, is a world-renowned medicinal chemist and entrepreneur. Dr. Priebe is a Professor of Medicinal Chemistry in the Section of Immunobiology and Drug Carriers in the Department of Bioimmunotherapy at The University of Texas MD Anderson Cancer Center. Dr. Priebe is the inventor of more than 50 patents and the author of more than 200 scientific publications. As the founder or founding scientist of 6 pharmaceutical companies, including three listed on NASDAQ, Dr. Priebe has been integral in advancing several drugs through the pipeline, five of which entered clinical development. Dr. Priebe led the research that formed basis for the development of agents with high brain uptake (BBB crossing) and is the discoverer of our lead drug candidate Berubicin. FOUNDER, CHAIRMAN OF THE SCIENTIFIC ADVISORY BOARD DR. WALDEMAR PRIEBE, PH.D. Dr. Sigmund Hsu, M.D. is fellowship trained and certified by the American Board of Psychiatry and Neurology, with extensive experience in the evaluation and treatment of neurological disorders in cancer patients. He specializes in primary brain tumors as well as brain and spinal cord metastases, cancer neurology and the treatment of chemotherapy neurotoxicity. Dr. Hsu has presented research at several national conferences, and his work has been published in numerous journals and textbooks. His most recent research has focused on novel therapies for recurrent primary CNS lymphoma, recurrent glioblastoma multiforme and intralumbar injections for cancer therapy, and he has several patents granted and pending for his treatments. Most uniquely, Dr. Hsu personally treated patients with Berubicin in the Phase 1 clinical trial sponsored by Reata, including one patient with a durable complete response who is still alive today. CNS PHARMACEUTICALS INC. SCIENTIFIC ADVISOR DR. SIGMUND HSU, M.D. scientific advisors Patrick Y Wen, MD is Professor of Neurology at Harvard Medical School, and Director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute in Boston, MA. He graduated from the Medical College of St. Bartholomew's Hospital, University of London, and completed his Internal Medicine training at University of London postgraduate hospitals, and Neurology residency through the Harvard-Longwood Neurology Training Program. His research focuses on novel treatments of brain tumors, especially targeted molecular agents. Dr Wen has authored or co-authored hundreds of peer-reviewed articles that have been published in journals such as Neurology, Neuro-Oncology, Current Opinion in Neurology, and Journal of Clinical Oncology. He serves on the Board of Directors and previously as President of the Society For Neuro-Oncology and SNO Executive Editor of Neuro-Oncology. CNS PHARMACEUTICALS INC. SCIENTIFIC ADVISOR DR. PATRICK Y. WEN, M.D.